cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sigilon Therapeutics Inc
4 own
6 watching
Current Price
$4.9
$-0.69
(-12.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
12.26M
52-Week High
52-Week High
20.93
52-Week Low
52-Week Low
3.77
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization12.26M
icon52-Week High20.93
icon52-Week Low3.77
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Sigilon Therapeutics Inc do?
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Sigilon Therapeutics Inc make?
News & Events about Sigilon Therapeutics Inc.
Zolmax
4 months ago
Canaccord Genuity Group initiated coverage on shares of Sigilon Therapeutics (NASDAQ:SGTX Get Rating) in a research note released on Wednesday, Benzinga reports. The brokerage issued a buy rating and a $6.00 price target on the stock. Sigilon Therapeutics Price Performance NASDAQ:SGTX opened at $0....
Ticker Report
4 months ago
Canaccord Genuity Group initiated coverage on shares of Sigilon Therapeutics (NASDAQ:SGTX Get Rating) in a research note released on Wednesday, Benzinga reports. The brokerage issued a buy rating and a $6.00 price target on the stock. Sigilon Therapeutics Price Performance NASDAQ:SGTX opened...
PR Newswire
1 year ago
Flagship Pioneering Expands Leadership Team with Appointment of Michael Severino as CEO-Partner Flagship Pioneering Expands Leadership Team with Appointment of Michael Severino as CEO-Partner PR Newswire CAMBRIDGE, Mass., April 13, 2022 CAMBRIDGE, Mass., April 13, 2022 /PRNewswire/ -- Flagship...
PR Newswire
1 year ago
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022 Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022 Ranks #2 Most Innovative Company in North America PR Newswire CAMBRIDGE, Mass., March...
PR Newswire
1 year ago
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs PR Newswire CAMBRIDGE, Mass., Feb. 28, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Sigilon Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Sigilon Therapeutics Inc shares?
plus_minus_icon
How can I buy Sigilon Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Sigilon Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Sigilon Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Sigilon Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Sigilon Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Sigilon Therapeutics Inc?
plus_minus_icon
What percentage is Sigilon Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Sigilon Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.9
$-0.69
(-12.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SQZ BIOTECHNOLOGIES CO
SQZ BIOTECHNOLOGIES CO
$0.57
$-0.02 (-2.68 %)
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$2.43
$0.17 (7.52 %)
ONCORUS INC
ONCORUS INC
$0.22
$0.02 (9.85 %)
Clene Inc
Clene Inc
$0.94
$-0.01 (-0.79 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SQZ BIOTECHNOLOGIES CO
SQZ BIOTECHNOLOGIES CO
$0.57
$-0.02 (-2.68 %)
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$2.43
$0.17 (7.52 %)
ONCORUS INC
ONCORUS INC
$0.22
$0.02 (9.85 %)
Clene Inc
Clene Inc
$0.94
$-0.01 (-0.79 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00